JAK2 and essential thrombocythemia: On the contrary, there was no significantly statistical difference, regarding unthrombosed compared to those developed thrombosis, in ET patients with JAK2 V617F positive mutation versus the JAK2 negative group (P > 0.05) or patients with cardiovascular risk factors versus patients with noncardiovascular risk factors (P > 0.05) (Table 3).